Analysis of the fate of SOX9-expressing cells through lineage tracing experiments. (A- B) Immunofluorescence for SOX9 in limbal (A) and corneal (B) sections of adult control mice. DAPI (blue) was used to counterstain nuclei. (C) Schematic of the genetic lineage tracing strategy. Tamoxifen (TX) was administered to label SOX9-expressing cells and their progeny. (D-F) Analysis of EYFP expression in the limbus (D-E) and cornea (F) of Sox9-EYFP adult mice. At 10 days after TX administration (10 DATX), discrete EYFP-positive clones are visible in the limbal region (D). By 20 DATX, these clones expand towards the peripheral cornea, with some cells reaching the outer epithelial layers at the limbus-cornea border (arrowhead in E). In the central cornea, EYFP-positive cells extend along the entire epithelium by 20 DATX (arrowhead in F). (G) Short-term whole mount X-gal staining of Sox9-LacZ eyes. The first LacZ-positive cells scattered across the limbal and corneal surface appeared at 3 DATX (arrows). (H) Long-term whole mount X-gal staining of Sox9-LacZ eyes. At 45 DATX, LacZ-positive stripes emerge from the limbus and extend into the peripheral cornea (arrow). At 60 DATX, circumferential clones are observed in the limbus (arrowheads). At 90 DATX, three clone types are visible: circumferential clones in the limbus (arrowheads), stripes from the limbus reaching the central cornea (arrow), and stripes without a base in the limbus (asterisk). At 365 DATX, the first two clone types are mainly observed, though in reduced numbers and larger sizes (see arrowheads and arrow as in the 90 DATX picture), with some stripes without a base in the limbus (asterisk). Scale bars in E and F represent 50 µm; scale bars in G and H represent 500 µm.